Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
Calithera Biosciences (CALA) will release its first quarter 2022 financial results on May 10, 2022. A conference call will follow at 2:00 p.m. PT to discuss these results and recent corporate highlights. Interested parties can access the press release and live audio webcast on Calithera's investor website. The company specializes in precision oncology and is advancing a pipeline of small molecule therapies targeting genetic vulnerabilities in cancer cells. Forward-looking statements indicate potential risks in clinical development and regulatory approvals.
- Anticipated financial results release may signal progress in clinical development.
- The company's focus on targeted therapies may address unmet medical needs.
- Risks and uncertainties could affect the advancement of product candidates.
- Potential delays in clinical trials may negatively impact stock price.
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s first quarter 2022 financial results will be released on Tuesday, May 10, 2022. Company management will host a conference call on Tuesday, May 10, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. The call may be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and referring to conference ID 4979639. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Calithera’s website for 30 days.
About Calithera
Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options.
Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in preclinical development and clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or be successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
CONTACTS:
Stephanie Wong
ir@Calithera.com
650-870-1063
INVESTORS:
Burns McClellan
Lee Roth
212.213.0006
lroth@burnsmc.com
FAQ
When will Calithera Biosciences release its first quarter 2022 financial results?
What is the purpose of the conference call scheduled for May 10, 2022?
How can I access the live audio webcast for Calithera's financial results?
What is the significance of Calithera's focus on precision oncology?
What risks does Calithera face in product development?
